Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P29622
UPID:
KAIN_HUMAN
Alternative names:
Kallikrein inhibitor; Peptidase inhibitor 4; Serpin A4
Alternative UPACC:
P29622; Q53XB5; Q86TR9; Q96BZ5
Background:
Kallistatin, also known as Serpin A4, plays a crucial role in regulating the human body's kallikrein-kinin system by inhibiting tissue kallikrein's amidolytic and kininogenase activities. This inhibition is facilitated through the formation of a stable complex between Kallistatin and the enzyme, alongside the generation of a C-terminal fragment post-cleavage at the reactive site by tissue kallikrein.
Therapeutic significance:
Understanding the role of Kallistatin could open doors to potential therapeutic strategies. Its ability to modulate the kallikrein-kinin system suggests its potential in treating diseases where this system plays a pivotal role.